8-K
filed January 8, 2024, 6:59 PM ET
ticker PACB
CIK 0001299130
earnings
confidence high
sentiment positive
materiality 0.75
PacBio reports record preliminary Q4 revenue $58.4M, up 113% YoY; Revio installed base 173
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
2023-FY EPS reported
-$1.21
revenue$200,521,000
- Preliminary full year 2023 revenue $200.5M, up 56% YoY; Q4 revenue $58.4M (+113% YoY).
- Shipped 44 Revio systems in Q4, total installed base 173; annualized pull-through ~$385K per system.
- Preliminary Q4 consumables revenue $18.9M (67% from Revio); instrument revenue $35.1M.
- Cash, equivalents, and investments $631M as of Dec 31, 2023.
- Reaffirms 40-50% annual revenue growth target through 2026, aiming for >$500M in 2026.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the full year ended December 31, 2023 results: revenue $200.5 million. Guidance reaffirmed.
- Period
- the full year ended December 31, 2023
- Revenue
- $200.5 million
- Guidance
- reaffirmed
- Result
- preliminary results
Exact text from the filing
announced preliminary unaudited revenue for the fourth quarter 2023 and full year 2023 of $58.4 million and $200.5 million
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the fourth quarter ended December 31, 2023 results: revenue $58.4 million. Guidance reaffirmed.
- Period
- the fourth quarter ended December 31, 2023
- Revenue
- $58.4 million
- Guidance
- reaffirmed
- Result
- preliminary results
Exact text from the filing
PacBio reported preliminary, unaudited revenue of approximately $58.4 million for its fourth quarter ended December 31, 2023.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.